Welcome!

News Feed Item

Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension

-- First liquid formulation clozapine for treatment-resistant schizophrenia

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz™ (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

"We are pleased to offer patients with treatment-resistant schizophrenia a new liquid formulation of clozapine that is FDA approved to treat this difficult condition," said Bruce C. Cozadd, chairman and CEO at Jazz Pharmaceuticals plc. "Versacloz is an important addition to our existing psychiatry product portfolio and offers physicians another treatment option to help patients with limited treatment options."

Versacloz is an atypical antipsychotic indicated for the treatment of people with schizophrenia who have failed to respond adequately to other therapies.(1) Versacloz is also approved to reduce the risk of recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder who are at chronic risk for re-experiencing suicidal behavior.(1) Versacloz has a unique, tasteless formulation and can be administered in an outpatient setting or under the supervision of a healthcare professional through an oral suspension. This formulation helps eliminate the mixing and matching of pill dosage strengths. In institutional settings, the formulation may help with confirmation of administration, and may reduce the possibility of "cheeking," hiding, or sharing the medication.

Because of the risk of agranulocytosis with clozapine therapy, Versacloz will be available only through a restricted program called the Versacloz Patient Registry, which ensures appropriate monitoring of white blood cell and absolute neutrophil count prior to delivery of the next refill of medication.(1) As part of its ongoing commitment to the psychiatry community, Jazz Pharmaceuticals, through the Versacloz Patient Registry and experienced Clinical Compliance Liaisons, will provide blood monitoring and reporting support services not typically offered by generic clozapine manufacturers.

"In my experience, some treatment-resistant schizophrenia patients may cycle through four or five typical and atypical antipsychotic treatments while failing to maintain adequate symptom control," said Gustavo Alva, MD, DFAPA, Medical Director at ATP Clinical Research. "When patients reach this stage, the next move matters – now with oral suspension Versacloz, we have another option to help patients."

The Food and Drug Administration (FDA) approval of Versacloz was based on general studies related to clozapine. Efficacy in treatment-resistant schizophrenia was established in a six-week active-controlled study in patients who had failed other antipsychotics. Efficacy in reducing recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder was demonstrated over a two-year treatment period in the InterSePT™ trial. As part of the New Drug Application filing for Versacloz, the FDA required a post-approval usability study to determine a patient's ability to self-administer the oral suspension.

Versacloz is distributed by Jazz Pharmaceuticals, Inc., a U.S. subsidiary of Jazz Pharmaceuticals plc.

INDICATION(1)
Versacloz is indicated for:

  • Treatment-resistant schizophrenia in severely ill patients. Because of the significant risk of agranulocytosis and seizure associated with its use, Versacloz should be used only in patients who have failed to respond adequately to standard antipsychotic treatment. Efficacy was established in a 6-week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics.
  • Reduction in the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state.  Efficacy was demonstrated over a two-year treatment period in the InterSePT™ trial.

BOXED WARNING IMPORTANT SAFETY INFORMATION

Agranulocytosis: Clozapine has caused agranulocytosis, which can lead to serious infection and death. Monitor white blood cell count (WBC) and absolute neutrophil count (ANC) prior to and during treatment with VERSACLOZ.  The ANC must be ≥ 2000/mm3 and the WBC must be ≥ 3500/mm3 for a patient to begin treatment. During treatment, discontinue and do not rechallenge if the ANC is < 1000/mm3 or the WBC is < 2000/mm3. Advise patients to immediately report symptoms consistent with agranulocytosis or infection (e.g., fever, weakness, lethargy, or sore throat).

 

Because of the risk of agranulocytosis, VERSACLOZ is available only through a restricted program called the VERSACLOZ Patient Registry.  Prescribers, patients, and pharmacies must enroll in this restricted program.  Further information is available at http://www.versaclozregistry.com or 1-877-329-2256.  

 

Orthostatic Hypotension, Bradycardia, Syncope: Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment.  Highest risk is during initial titration, particularly with rapid dose escalation and can occur with the first dose (12.5 mg/day).  Titrate slowly and use divided dosages.  Use VERSACLOZ cautiously in patients with cardiovascular/cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications).

 

Seizures: Seizures have occurred with clozapine treatment.  The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing.  Use cautiously in patients with a history of seizures or predisposing risk factors (CNS pathology, medications that lower the seizure threshold, alcohol abuse).  Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others.

 

Myocarditis and Cardiomyopathy: Fatal myocarditis and cardiomyopathy have occurred with clozapine treatment.  Discontinue and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with VERSACLOZ-related myocarditis or cardiomyopathy should not be rechallenged.  Consider the possibility of myocarditis or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur.

 

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.  VERSACLOZ is not approved for this condition.  

  • Contraindications include:(1)
    • History of clozapine-induced agranulocytosis or severe granulocytopenia
    • Known hypersensitivity to clozapine or any other component of VERSACLOZ
  • Eosinophilia has occurred, usually during the first month of treatment with clozapine. In clinical trials, approximately 1% of patients developed eosinophilia.  Discontinue VERSACLOZ if organ involvement (e.g., myocarditis, pancreatitis, hepatitis, colitis, nephritis) occurs.(1)
  • QT interval prolongation, sometimes life-threatening, has occurred with clozapine. Consider additional risk factors for prolonged QT interval (disorders and drugs) including patient and family history, treatment with other medications that cause QT prolongation or inhibit the metabolism of VERSACLOZ and electrolyte abnormalities.  Discontinue use if the QTc interval exceeds 500 msec or if the patient experiences symptoms consistent with Torsades de Pointes or other arrhythmias, (e.g., syncope, presyncope, dizziness, or palpitations).(1)
  • Atypical antipsychotics, including clozapine have been associated with metabolic changes, including:(1)
    • Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme associated with ketoacidosis and hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including clozapine.  Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Monitor glucose regularly in patients with or at risk for diabetes.
    • Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics.  Baseline and periodic follow-up lipid evaluations are recommended.
    • Weight Gain: Weight gain has occurred in clinical trials with clozapine.  Monitor weight during treatment.
  • Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported with administration of antipsychotics, including clozapine.  Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability.  Additional signs may include elevated creatine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure.  If NMS occurs, immediately discontinue VERSACLOZ, manage with intensive symptomatic treatment, monitor closely, and assess for comorbidities.(1)
  • Patients have experienced transient, clozapine-related fever during therapy, often within the first 3 weeks of treatment.  Evaluate patients with fever for agranulocytosis, infection, or NMS.(1)
  • Consider pulmonary embolism (PE) if respiratory distress, chest pain, or deep vein thrombosis occur.(1)
  • CNS and peripheral anticholinergic toxicity can occur with VERSACLOZ.  Use cautiously in the presence of narrow-angle glaucoma, concomitant anticholinergic drugs, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions.(1)
  • Advise caution when operating machinery, including automobiles.  Consider reducing the dose if cognitive or motor interference occurs.(1)
  • Warnings and precautions also include the risk of tardive dyskinesia, caution in patients with risk factors for cerebrovascular adverse reactions and the need to monitor for recurrence of psychosis and cholinergic rebound after abrupt discontinuation of VERSACLOZ.(1)
  • Common adverse reactions (>5%) across clozapine clinical trials were: CNS reactions, (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions, (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions, (constipation and nausea); and fever.(1)

Please click here to see the full Prescribing Information for important information about Versacloz, including BOXED Warning.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz™ (clozapine, USP) oral suspensions, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S. and expects to launch Defitelio™ (defibrotide) in the European Union over the course of 2014. The company has product candidates in development in its sleep and hematology/oncology franchises. For further information, see www.jazzpharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the therapeutic and commercial potential of Versacloz, the expected launch of Defitelio in the European Union and the timing thereof, and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the possibility that the company may fail to realize the anticipated benefits from Versacloz; the company's ability to successfully launch and commercialize Defitelio in a timely manner; the company's ability to successfully manage the risks associated with integrating Defitelio and any other products or product candidates the company may acquire in the future into the company's product portfolio; as well as risks related to future opportunities and plans; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and future filings and reports by the company. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

References:

  1. Versacloz™ Prescribing Information. Palo Alto, CA. Jazz Pharmaceuticals. 2013.

Versacloz is a trademark of Jazz Pharmaceuticals plc or its subsidiaries.

InterSePT is a trademark of Novartis Pharmaceuticals Corporation.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.